Skip to main content
SpringerLink
Log in

Comparison of brimonidine/ latanoprost and timolol/ dorzolamide: Two randomized, double-masked, parallel clinical trials

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Two double-masked, randomized, parallel, multicenter trials of similar design were conducted to compare the IOP-lowering efficacy of dual therapy with brimonidine 0.2% and latanoprost 0.005% with the fixed combination of timolol 0.5%/dorzolamide 2% in patients with glaucoma or ocular hypertension. The combination of brimonidine and latanoprost produced significantly greater mean IOP reductions at each visit in both trials. In study 1, the mean reduction at peak drug effect after 6 weeks was 9.2 mm Hg (34.7%) with brimonidine and latanoprost and 6.7 mm Hg (26.1%) with timolol/dorzolamide (P=.024); respective reductions at week 12 were 9.0 mm Hg (33.9%) and 6.5 mm Hg (25.3%) (P=.044). At the month 1 visit in study 2, the mean peak IOP reduction was 10.6 mm Hg (39.0%) with dual therapy and 6.3 mm Hg (25.1%) with the fixed combination (P=.001). After 3 months, reductions were 9.1 mm Hg (33.4%) and 6.6 mm Hg (26.3%) (P=.047). In these studies, the combination of brimonidine and latanoprost provided IOP control superior to that of the fixed combination of timolol/dorzolamide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kobelt G. Comparative data for all countries. In: Jonsson B, Kriegelstein G, eds.Primary Open-Angle Glaucoma. Differences in International Treatment Patterns and Costs. Oxford, England: ISIS Medical Media; 1998:116–126.

    Google Scholar 

  2. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamidetimolol combination versus the concomitant administration of its components.Ophthalmology. 1998;105:1936–1944.

    Article  PubMed  CAS  Google Scholar 

  3. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients.Am J Ophthalmol. 1999;127:20–26.

    Article  PubMed  CAS  Google Scholar 

  4. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results.Clin Ther. 2000;22:103–111.

    Article  PubMed  CAS  Google Scholar 

  5. Lee DA, Gornbein J. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated IOP in a large, open-label community trial.J Glaucoma. 2001;10:220–226.

    Article  PubMed  CAS  Google Scholar 

  6. Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.Ophthalmology. 2002;109:307–315.

    Article  PubMed  Google Scholar 

  7. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.Clin Ther. 2001;23:604–620.

    Article  PubMed  CAS  Google Scholar 

  8. Simmons ST, Samuelson TW. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma.Clin Ther. 2000;22:388–399.

    Article  PubMed  CAS  Google Scholar 

  9. Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post-hoc analysis of an open-label community trial.J Ocul Pharmacol Ther. 2000;16:3–18.

    PubMed  CAS  Google Scholar 

  10. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom, and the United States.Surv Ophthalmol. 1997;41(suppl 2):S105-S110.

    Article  PubMed  Google Scholar 

  11. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol.Ophthalmology. 1995; 102:1743–1752.

    PubMed  CAS  Google Scholar 

  12. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States.Ophthalmology. 1996;103:138–147.

    PubMed  CAS  Google Scholar 

  13. Martin L. Clinical experience with latanoprost: a retrospective study of 153 patients.Acta Ophthalmol Scand. 1999;77:336–339.

    Article  PubMed  CAS  Google Scholar 

  14. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.Am J Ophthalmol. 2000;130:429–440.

    Article  Google Scholar 

  15. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures.Am J Ophthalmol. 1998;126:487–497. Published erratum appears inAm J Ophthalmol. 1999;127:120.

    Article  Google Scholar 

  16. Walters TR, Shapiro A, Mroz M. A comparison of the efficacy and tolerability of brimonidine/ latanoprost versus timolol/latanoprost dual therapy.Invest Ophthalmol Vis Sci. 2000;41:S514. Abstract 2736.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. John A. Moran Eye Center, University of Utah, Salt Lake City, Utah

    Norman Zabriskie MD

  2. Department of Ophthalmology, University of Tennessee at Memphis, 956 Court Ave., 38163, Memphis, Tennessee

    Peter A. Netland MD, PhD

Authors
  1. Norman Zabriskie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter A. Netland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zabriskie, N., Netland, P.A. Comparison of brimonidine/ latanoprost and timolol/ dorzolamide: Two randomized, double-masked, parallel clinical trials. Adv Therapy 20, 92–100 (2003). https://doi.org/10.1007/BF02850256

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850256

Keywords

Search

Navigation